Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection Dr. Divya Colin4 May 2025 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has granted approval to...
Revise Phase III protocol: CDSCO Panel Tells Mankind Over Roflumilast Cream Dr. Divya Colin27 April 2025 5:45 PM ISTNew Delhi: Responding to the proposal presented by Mankind Pharmaceutical to manufacture and market selective phosphodiesterase-4 inhibitor...
Psoriasis Patients at Higher Risk of Metabolic and Cardiovascular Conditions, Study Shows Medha Baranwal20 March 2025 9:00 PM ISTChina: A recent study analyzing hospitalized patients in China has highlighted the complex comorbidity patterns associated with moderate-to-severe...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis Ruchika Sharma18 Feb 2025 3:42 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Tildrakizumab Sustains Long-Term Efficacy for Scalp Psoriasis Treatment, reveals research Dr Riya Dave1 Jan 2025 8:15 PM ISTResearchers have established that tildrakizumab, an anti-interleukin-23 p19 antibody, can be used to maintain long-term efficacy and safety for...
New Clinical Trial Supports QX004N's Safety and Effectiveness for Patients With Plaque Psoriasis Medha Baranwal25 Dec 2024 8:30 PM ISTChina: A new randomized clinical trial has demonstrated that QX004N, a humanized anti-IL-23 monoclonal antibody, offers superior safety and efficacy...
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
JAMA Study Finds Deucravacitinib Effective and Safe for Psoriasis Patients Jacinthlyn Sylvia9 Dec 2024 8:00 PM ISTThis recent 3-year study revealed that deucravacitinib which is an oral treatment for moderate to severe plaque psoriasis to offer a sustainable and...
Deucravacitinib Found to Be Safe and Effective for Psoriasis Over 3 Years: JAMA Dr Riya Dave5 Dec 2024 8:15 PM ISTResearchers have found that deucravacitinib for long-term treatment is well tolerated and has a sustained clinical response in the management of...
